EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Vertex Pharmaceuticals's enterprise value is $115,357 Mil.
Vertex Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was $11,100 Mil. Therefore, Vertex Pharmaceuticals's EV-to-Revenue for today is 10.39.
The historical rank and industry rank for Vertex Pharmaceuticals's EV-to-Revenue or its related term are showing as below:
VRTX'
s EV-to-Revenue Range Over the Past 10 Years
Min: 5.66 Med: 11.74 Max: 52.73
Current: 10.39
During the past 13 years, the highest EV-to-Revenue of Vertex Pharmaceuticals was 52.73. The lowest was 5.66. And the median was 11.74.
VRTX's EV-to-Revenue is ranked worse than 55.89% of 993
companies
in the Biotechnology industry
Industry Median: 8.02
vs VRTX: 10.39
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Vertex Pharmaceuticals's EV-to-Revenue
For the Biotechnology subindustry, Vertex Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vertex Pharmaceuticals's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Vertex Pharmaceuticals's EV-to-Revenue falls into.
Vertex Pharmaceuticals's current Enterprise Value is $115,357 Mil.
Vertex Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $11,100 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vertex Pharmaceuticals's share price for today is $474.29.
Vertex Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $42.86.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vertex Pharmaceuticals EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Vertex Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VRTX has been successfully added to your 